Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Payables (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Payables for 16 consecutive years, with $3.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables rose 86.37% year-over-year to $3.7 million, compared with a TTM value of $3.7 million through Sep 2025, up 86.37%, and an annual FY2024 reading of $1.4 million, down 59.9% over the prior year.
  • Payables was $3.7 million for Q3 2025 at China Pharma Holdings, up from $1.9 million in the prior quarter.
  • Across five years, Payables topped out at $6.4 million in Q3 2022 and bottomed at $397543.0 in Q2 2022.
  • Average Payables over 5 years is $2.5 million, with a median of $2.0 million recorded in 2024.
  • The sharpest move saw Payables tumbled 69.48% in 2021, then surged 839.46% in 2022.
  • Year by year, Payables stood at $1.5 million in 2021, then surged by 196.57% to $4.5 million in 2022, then fell by 23.52% to $3.4 million in 2023, then tumbled by 59.9% to $1.4 million in 2024, then soared by 171.26% to $3.7 million in 2025.
  • Business Quant data shows Payables for CPHI at $3.7 million in Q3 2025, $1.9 million in Q2 2025, and $3.3 million in Q1 2025.